$1.51
0.00%
Nasdaq, Fri, Sep 06 2024
ISIN
US00847L1008
Symbol
AGRX
Sector
Industry

Agile Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
about one month ago
Agile Therapeutics has combined with Insud Pharma's US Subsidiary, Exeltis USA, Inc., expanding an already significant women's health/contraceptive portfolio
Neutral
GlobeNewsWire
about 2 months ago
Dublin, Aug. 07, 2024 (GLOBE NEWSWIRE) -- The "Agile Leadership for Pharma and Biopharma Professionals in a hybrid world Training Course" conference has been added to ResearchAndMarkets.com's offering.
Neutral
Business Wire
3 months ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Agile Therapeutics, Inc. (OTC: AGRX) to Insud Pharma, S.L. Under the terms of the proposed transaction, shareholders of Agile will receive $1.52 in cash for each share of Agile that they own. KSF is seeking to det...
Neutral
Business Wire
3 months ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Agile Therapeutics, Inc. (OTCQB: AGRX) to Insud Pharma, S.L. for $1.52 per share in cash is fair to Agile shareholders. Halper Sadeh encourages Agile shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-006...
Neutral
GlobeNewsWire
3 months ago
Agile Therapeutics will combine with Insud Pharma's US Subsidiary, Exeltis, expanding an already significant Women's Health/contraceptive portfolio
Neutral
GlobeNewsWire
5 months ago
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2024 and provided a corporate update.
Neutral
Seeking Alpha
6 months ago
Agile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Call Transcript
Neutral
GlobeNewsWire
6 months ago
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2024 from Decreased Demand in Fourth Quarter 2023 Management to Host Conference Call Today, Thursday, March 28, 2024 at 8:30 a....

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today